Intercept Pharmaceuticals, Inc.

NasdaqGS:ICPT 株式レポート

時価総額:US$794.7m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Intercept Pharmaceuticals マネジメント

マネジメント 基準チェック /34

Intercept Pharmaceuticals'の CEO はJerry Dursoで、 Jan2021年に任命され、 の在任期間は 2.83年です。 の年間総報酬は$ 4.46Mで、 16%給与と84%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の0.12%を直接所有しており、その価値は$ 984.47K 。経営陣と取締役会の平均在任期間はそれぞれ2.7年と8.7年です。

主要情報

Jerry Durso

最高経営責任者

US$4.5m

報酬総額

CEO給与比率16.0%
CEO在任期間2.8yrs
CEOの所有権0.1%
経営陣の平均在職期間2.7yrs
取締役会の平均在任期間8.7yrs

経営陣の近況

Recent updates

Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Jun 08
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive

Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Apr 11
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Dec 20
Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?

Intercept touts Ocaliva benefit in transplant-free survival in liver disease type

Sep 20

Intercept cuts debt further with deal to exchange convertible notes

Sep 02

Intercept reduces debt with repurchases of $327.9M convertible notes

Aug 19

Intercept Pharmaceuticals: Too Risky To Buy At This Stage

Aug 13

Intercept Pharma Q2 2022 Earnings Preview

Aug 02

Intercept to resubmit for FDA approval of NASH candidate after new analysis

Jul 07

Intercept: Increase Of Ocaliva Sales And A Few Catalysts

May 23

Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

May 10
Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH

Mar 05

Intercept names Andrew Saik as chief financial officer

Jun 07

Intercept Pharmaceuticals slides as FDA restricts Ocaliva use

May 26

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?

May 11
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?

CEO報酬分析

Intercept Pharmaceuticals の収益と比較して、Jerry Durso の報酬はどのように変化したか?
日付総報酬給与会社業績
Sep 30 2023n/an/a

-US$57m

Jun 30 2023n/an/a

-US$159m

Mar 31 2023n/an/a

-US$173m

Dec 31 2022US$4mUS$715k

-US$175m

Sep 30 2022n/an/a

-US$202m

Jun 30 2022n/an/a

-US$115m

Mar 31 2022n/an/a

-US$120m

Dec 31 2021US$8mUS$691k

-US$136m

Sep 30 2021n/an/a

-US$144m

Jun 30 2021n/an/a

-US$193m

Mar 31 2021n/an/a

-US$231m

Dec 31 2020US$4mUS$600k

-US$273m

Sep 30 2020n/an/a

-US$321m

Jun 30 2020n/an/a

-US$339m

Mar 31 2020n/an/a

-US$347m

Dec 31 2019US$4mUS$573k

-US$345m

Sep 30 2019n/an/a

-US$335m

Jun 30 2019n/an/a

-US$314m

Mar 31 2019n/an/a

-US$318m

Dec 31 2018US$3mUS$541k

-US$309m

Sep 30 2018n/an/a

-US$333m

Jun 30 2018n/an/a

-US$341m

Mar 31 2018n/an/a

-US$352m

Dec 31 2017US$4mUS$441k

-US$360m

報酬と市場: Jerryの 総報酬 ($USD 4.46M ) は、 US市場 ($USD 3.39M ) の同規模の企業の平均を上回っています。

報酬と収益: Jerryの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Jerry Durso (55 yo)

2.8yrs

在職期間

US$4,455,463

報酬

Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jerome Durso
President2.8yrsUS$4.46m0.12%
$ 984.5k
Andrew Saik
Chief Financial Officer2.4yrsUS$1.39m0.055%
$ 437.4k
Jared Freedberg
General Counsel2.8yrsUS$1.31m0.13%
$ 1.1m
Linda Richardson
Executive VP & Chief Commercial Officer2.8yrsUS$1.34m0.040%
$ 317.4k
M. Berrey
President of Research & Development and Chief Medical Officer2.4yrsUS$1.61m0.068%
$ 538.6k
Rocco Venezia
Chief Accounting Officer & Treasurer2.7yrsUS$856.23k0.061%
$ 483.6k
Nareg Sagherian
Executive Director of Global Investor Relations1.9yrsデータなしデータなし
David Ford
Chief Human Resources Officer6.5yrsUS$1.91m0.036%
$ 285.7k
Mark Pruzanski
Founder2.8yrsUS$6.43m1.48%
$ 11.8m
Paul Nitschmann
Senior Vice President of Regulatory Affairsno dataデータなしデータなし
Kathleen Munster
Chief Quality Officer & SVP of Technical Operationsless than a yearデータなしデータなし
Michael Blash
Senior Vice President of Corporate Affairsless than a yearデータなしデータなし

2.7yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: ICPTの経営陣は 経験豊富 であると考えられます ( 2.7年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Jerome Durso
President2.5yrsUS$4.46m0.12%
$ 984.5k
Mark Pruzanski
Founder21.8yrsUS$6.43m1.48%
$ 11.8m
Daniel Bradbury
Independent Chairman7.3yrsUS$327.39k0.056%
$ 447.4k
Glenn Sblendorio
Independent Director9.8yrsUS$332.39k0.056%
$ 445.5k
Luca Benatti
Independent Director9.3yrsUS$327.39k0.061%
$ 484.3k
Srinivas Akkaraju
Independent Director11.1yrsUS$317.39k0.091%
$ 719.8k
Gino Santini
Lead Independent Director8yrsUS$337.39k0.057%
$ 449.2k
Alan Hofmann
Member of the Scientific Advisory Boardno dataデータなしデータなし
Scott L. Friedman
Member of the Scientific Advisory Boardno dataデータなしデータなし
Massimo Pinzani
Member of the Scientific Advisory Boardno dataデータなしデータなし
Aldo Roda
Member of the Scientific Advisory Boardno dataデータなしデータなし
Keith Gottesdiener
Independent Director7.3yrsUS$322.39k0.059%
$ 469.7k

8.7yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: ICPTの 取締役会経験豊富 であると考えられます ( 8.7年の平均在任期間)。